AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 232 min read$ZYME

Zymeworks Inc. (ZYME): Completion of Acquisition or Disposition of Assets

Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Zymeworks Completes Acquisition of Theravance Biopharma • Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) Vancouver, British Columbia (September 23, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portf

Original reporting
SEC EDGAR 8-K
Published Sep 23, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$ZYME
Bullish
high confidence
Mentioned
$ZYME
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ZYMEBullishHigh
01

Why it matters

The transaction broadens Zymeworks' product portfolio and royalty income, potentially enhancing cash flow and valuation.

02

Market read

The acquisition is a material corporate event for Zymeworks, likely influencing its share price and sector dynamics.

03

What to watch

Financing terms and potential regulatory hurdles for the acquired assets.

Relevance 8/10Novelty 8/10Timing: today

Background

Zymeworks announced the completion of its previously disclosed acquisition of Theravance Biopharma via an SEC Form 8‑K filing.

Company-level read

Ticker impact

$ZYMEBullishHigh confidence
Context

Zymeworks completed its acquisition of Theravance Biopharma, adding new assets and royalty streams.

Expected impact

upward pressure in the near term as investors price in synergies.

Evidence & confidence

Primary 8‑K filing, first public disclosure of the deal, material for a biotech of this size.

Market effects

Sector

Biotech sector may see increased M&A activity as companies seek diversified revenue streams.

Regional

North American biotech investors likely to react positively.

Global

Adds to global interest in antibody‑drug conjugate platforms.

Counterpoint

What could challenge this read

Deal could dilute focus on core programs and increase integration risk.

Key entities

  • company
    Zymeworks Inc.

    Biotech firm completing the acquisition.

  • company
    Theravance Biopharma

    Acquired biotech assets and royalty interests.

Read at source← All news

Related articles

SEP 8
$ZYMEMedAI 8/10

Zymeworks at Wells Fargo conference: cash flow, zanidatamab drive

Zymeworks (ZYME) presented at the Wells Fargo Healthcare Conference, highlighting its strategy focused on zanidatamab, royalty income, and acquisitions. Zanidatamab received FDA approval for gastric cancer, with Jazz Pharmaceuticals raising its peak sales estimate to $3B-$5B. Zymeworks raised $600M in debt, repurchased 10.5M shares, and plans to acquire Theravance Respiratory. Management expects profitability in 2026, with analysts forecasting 34% upside.

investing.com3 min
AUG 26
$ZYMEHighAI 9/10

FDA approves new indications for Ziihera

Zymeworks (ZYME) announced that its partner, Jazz Pharmaceuticals (JAZZ), received FDA approval for two Ziihera-containing regimens for treating HER2-positive gastroesophageal adenocarcinoma. This is the second FDA approval for zanidatamab in under two years, validating Zymeworks' Azymetric platform.

thepharmaletter.com2 min
AUG 26
$ZYMEHighAI 9/10

ZYME Looks 47.1% Overvalued on GF Value™

Zymeworks Inc (ZYME) shares rose 8% after FDA approval of Jazz Pharmaceuticals' Ziihera, triggering a $250M payment. ZYME's P/S ratio is 59.82x, higher than its historical median. Analysts set price targets at $55 and $40. The company's GF Score is 60, indicating moderate fundamental quality. Insiders sold $4.7M in shares over the past year.

gurufocus.com2 min
AUG 26
$ZYMEHighAI 9/10

H.C. Wainwright raises Zymeworks stock price target to $55 on FDA approval

H.C. Wainwright raised its price target on Zymeworks (ZYME) to $55 from $51, maintaining a Buy rating after FDA approval of Ziihera for HER2-positive gastroesophageal adenocarcinoma. The stock is up 85% over the past year. The approval triggers a $250 million payment from Jazz Pharmaceuticals (JAZZ). Analysts predict 188% revenue growth for FY2026. Zymeworks also announced an acquisition of Theravance Biopharma for $929 million.

investing.com2 min
AUG 25
$ZYMEHighAI 8/10

Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab

Zymeworks (ZYME) shares rose 4% in pre-market trading ahead of an FDA decision on zanidatamab, a HER2-targeting antibody, with a PDUFA target date of August 25, 2026. Approval could trigger a $250 million milestone payment and up to $190 million more in other markets. Analysts have increased price targets ahead of the decision. The company is also pursuing a $929 million acquisition of Theravance Biopharma, expected to close in late 2026.

yahoo.com2 min